Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study

The Democratic Republic of the Congo adopted the integrase inhibitor dolutegravir (DTG) as part of its preferred first-line HIV treatment regimen in 2019. This study aimed to identify predictors of viral non-suppression among HIV-infected patients under a DTG-based regimen in the context of ongoing...

Descripción completa

Detalles Bibliográficos
Autores principales: Buju, Roger T., Akilimali, Pierre Z., Kamangu, Erick N., Mesia, Gauthier K., Kayembe, Jean Marie N., Situakibanza, Hippolyte N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834045/
https://www.ncbi.nlm.nih.gov/pubmed/35162109
http://dx.doi.org/10.3390/ijerph19031085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834045/
https://www.ncbi.nlm.nih.gov/pubmed/35162109
http://dx.doi.org/10.3390/ijerph19031085

Ejemplares similares